UroGen Pharma Financials - Benzinga

UroGen Pharma Ltd

URGNNASDAQ

Trade with Public

Trade with Public

$44.42

1.032.37%

At close: Sep 2, 5:00 PM EST

$43.85

-0.57-1.28%

After Hours: 5:23 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

UroGen Pharma Financials

UroGen Pharma (URGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
UroGen Pharma Q2 EPS $(0.28) Beats $(0.29) Estimate, Sales $72.456M Beat $63.526M Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 73.33 percent increase over losses of $(1.05) per share from the

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
UroGen Pharma Q1 EPS $(0.47) Beats $(0.48) Estimate, Sales $50.959M Beat $44.820M Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 48.91 percent increase over losses of $(0.92) per share from the

Benzinga Newsdesk

UroGen Pharma: Q4 Earnings Insights

Benzinga Insights

PRO
UroGen Pharma Q4 EPS $(0.54) Misses $(0.53) Estimate, Sales $37.837M Miss $39.922M Estimate

Benzinga Newsdesk

Earnings Scheduled For March 2, 2026

Benzinga Insights